ESMO 2026 | Combination therapy with AR-targeted and PSMA-targeted agents in prostate cancer

Name: Combination therapy with AR-targeted and PSMA-targeted agents in prostate cancer
Uploaded: 2026-10-26T00:00:00Z
Duration: 1 min 25 s

Alice Bernard-Tessier • 26 Oct 2026

ESMO 2026

Genitourinary Cancer Prostate Cancer

Alice Bernard-Tessier, MD, Institut Gustave Roussy, Villejuif, France, discusses the potential of combining androgen receptor (AR)-targeted therapies with prostate-specific membrane antigen (PSMA)-targeted radioligand therapy, noting that while AR inhibition may increase PSMA levels, it is unclear if this translates to a response to lutetium PSMA. Current data do not support a direct link between PSMA upregulation and response to lutetium PSMA, but rather points to a potential synergy between AR inhibition and radiation-induced DNA damage. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.